Press Releases Details

Silence Therapeutics Technology Licensee Quark Pharmaceuticals announces First Patient Dosed in Phase 3 Clinical Trial for Acute Kidney Injury

11 July 2018

Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, notes Quark Pharmaceutical, Inc's ("Quark") press release "Quark Pharmaceuticals, Inc Announces First Patient Dosed in Phase 3 Clinical Trial of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery". Quark also reported that they have reached agreement with the FDA on the overall Phase 3 trial design with a new primary endpoint.

Quark holds a license to Silence's chemical modification technology. Silence is eligible to receive either approximately 1.5%-4% royalties from Quark (on QPI-1002) plus milestones, or 15% of the clinical, regulatory and commercial milestone payments and royalties received by Quark from its partner Novartis.

Annalisa Jenkins, Executive Chair of the Board of Directors, said: "We are pleased to see the pipeline progress made by Quark Pharmaceuticals.  Based upon positive data observed in their Phase 2 program, Quark have successfully transitioned to a major pivotal Phase 3 program for patients at high risk post cardiac surgery requiring prevention of Acute Kidney Injury (AKI). This significant global siRNA program includes proprietary chemical modification technology developed by Silence Therapeutics."

Quark's full announcement can be found here: http://quarkpharma.com/?p=12506

Enquiries:

Notes to Editors

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. For more information, please visit: http://www.silence-therapeutics.com/